Atlas Trials

Genor Biopharma Co., Ltd.

24 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Genor Biopharma Co., Ltd.

RecordFirmDate
A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors (NCT06934616)Genor Biopharma Co., Ltd.2025-04-24
A Study of [14C]GB491 in Male Healthy Subjects (NCT05860582)Genor Biopharma Co., Ltd.2022-09-14
A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor (NCT05332574)Genor Biopharma Co., Ltd.2022-05-17
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer (NCT05851014)Genor Biopharma Co., Ltd.2022-01-14
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer (NCT05054751)Genor Biopharma Co., Ltd.2021-09-10
A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. (NCT04923048)Genor Biopharma Co., Ltd.2021-08-31
A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer (NCT05337657)Genor Biopharma Co., Ltd.2021-06-02
Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ® (NCT04905667)Genor Biopharma Co., Ltd.2019-11-13
A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis Patients (NCT04179513)Genor Biopharma Co., Ltd.2019-08-15
A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive (NCT03808857)Genor Biopharma Co., Ltd.2019-05-23
Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer (NCT03977090)Genor Biopharma Co., Ltd.2019-04-04
Phase Ⅰ Clinical Study Protocol of GB223 Monoclonal Antibody Injection (NCT04178044)Genor Biopharma Co., Ltd.2018-11-16
Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226) (NCT03639181)Genor Biopharma Co., Ltd.2018-10-15
Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226) (NCT03623581)Genor Biopharma Co., Ltd.2018-09-06
Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) (NCT03502629)Genor Biopharma Co., Ltd.2018-07-02
Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects (NCT04178070)Genor Biopharma Co., Ltd.2017-11-06
Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma (NCT03374007)Genor Biopharma Co., Ltd.2017-10-19
Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for Injection (NCT04178850)Genor Biopharma Co., Ltd.2017-10-13

Track Genor Biopharma Co., Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.